NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 127 filers reported holding NURIX THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,213,223 | -21.8% | 663,260 | -0.6% | 0.00% | 0.0% |
| Q2 2023 | $6,667,496 | +111958.8% | 667,417 | -0.4% | 0.00% | 0.0% |
| Q1 2023 | $5,950 | -21.5% | 669,973 | -3.0% | 0.00% | -33.3% |
| Q4 2022 | $7,581 | -99.9% | 690,365 | +24.9% | 0.00% | 0.0% |
| Q3 2022 | $7,201,000 | +75.1% | 552,656 | +70.3% | 0.00% | +50.0% |
| Q2 2022 | $4,113,000 | +186.2% | 324,585 | +208.0% | 0.00% | – |
| Q1 2022 | $1,437,000 | -42.3% | 105,391 | +11.2% | 0.00% | -100.0% |
| Q4 2021 | $2,492,000 | -32.0% | 94,777 | -7.0% | 0.00% | 0.0% |
| Q3 2021 | $3,667,000 | -7.1% | 101,859 | -31.5% | 0.00% | 0.0% |
| Q2 2021 | $3,946,000 | -9.4% | 148,759 | +6.2% | 0.00% | 0.0% |
| Q1 2021 | $4,354,000 | +34.0% | 140,057 | +41.7% | 0.00% | 0.0% |
| Q4 2020 | $3,250,000 | +39.2% | 98,841 | +47.9% | 0.00% | 0.0% |
| Q3 2020 | $2,334,000 | – | 66,850 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |